Cadila Pharmaceuticals Ltd

India plans to return to the Russian drug market and invest about $ 100 million in the production of several vaccines and biodrugs, as Pankaj Patel, the Head of Cadila Healthcare and President of the Federation of Chambers of Commerce and Industry of the Republic of India, told in his interview with RIA Novosti during the Eastern Economic Forum.

07 September 2017

The Indian generic company Cadila Pharmaceuticals will build a plant in Puschino, the Moscow region, withl investments totalling about $ 50 million, the Moscow Region Governor Andrei Vorobyov said to the RNC news agency. The press service of the Ministry of Investment and Innovation of the Moscow region confirmed this information to the Vademecum, although it could not provide more detailed commentary.

05 June 2017

India-based Cadila Pharmaceuticals is looking at investing up to $150 million to build a pharmaceutical manufacturing plant in the Astrakhan region of Russia.

Cadila Managing Director Rajiv Modi visited the Russian region and signed a protocol with Astrakhan representative Konstantin Markelov. Modi was part of a delegation from the Indian state of Gujarat, which has a cooperation agreement with Astrakhan.

The financial details and the capacity and of the proposed plant were not revealed. The Pharma Letter website, citing sources close to the Astrakhan region, said Cadila’s investments may reach $150 million.

According to the website, the proposed plant is in line with Cadila’s foreign expansion plans, which involve the increase of sales and launch of plants in the emerging markets of Russia, China and African countries. The new plant would most likely produce the majority of the company’s drugs and in particular its anti-tuberculosis range, the website added. 

15 March 2013
150.0 mln
Astrakhan region

Investor profile

Cadila Pharmaceuticals Ltd

Ahmedabad, India

T: +91 27 1822 5001

Contact: Dr Rajiv I Modi, Chairman and Managing Director

Cadila Pharmaceuticals is a medical business based in India. The firm also conducts research and development in the drug sector and also produces some biopharmaceutical products.